The revolving door turns again. After a two-year stint running the Food and Drug Administration, Scott Gottlieb has joined the board of directors at Pfizer, giving the world's largest drug maker crucial insights into the inner workings of the Trump administration as it attempts to contain national angst over the rising cost of medicines.
And in doing so, Gottlieb is also picking up where he left before joining the agency, since he had been on the board of several smaller pharmaceutical companies and was also a partner at a venture capital firm that invests in life sciences companies.
"This is classic and it's not surprising," said Sidney Wolfe, a founder of Public Citizen Health Research Group and a long-time FDA watchdog, who had expressed concern about Gottlieb's ties to industry before joining the agency. "Philosophically, he's returning to the ecosystem where he's most comfortable. And he'll get paid very well for it, too."
Also at Financial Times [ft.com].
Related: What a Gottlieb-Led FDA Might Mean for the Pharmaceutical Industry [soylentnews.org]
FDA Nominee is a Proponent of "Adaptive Trials" [soylentnews.org]
Drug Approvals Sped Up in 2017 [soylentnews.org]
Koch-Backed Groups Urge Congress to Pass "Right to Try" Legislation [soylentnews.org]
FDA Labels Kratom an Opioid [soylentnews.org]
FDA Has Named Names of Pharma Companies Blocking Cheaper Generics [Updated] [soylentnews.org] (including Pfizer)
U.S. to Make More Drugs Easily Available, Cutting Role Docs Play [soylentnews.org]